logo

BioMed Research International

BioMed Research International / 2013 / Article / Tab 2

Review Article

The Treatment Outcome and Radiation-Induced Toxicity for Patients with Head and Neck Carcinoma in the IMRT Era: A Systematic Review with Dosimetric and Clinical Parameters

Table 2

Published studies with either IMRT or conventional techniques. Data included concomitant chemotherapy or not, follow-up, and radiation-induced toxicity.
Study Radiation treatment Concurrent
chemotherapy
No. of patients (%)		 Median
followup (range)		 Toxicity (≥GrII) Mean parotid- gland dose
MucositisXerostomia
AcuteLateAcuteLate
Studer et al. [24]†IMRTYes (86%)16 mths (4–44 mths)65%——— 
Lee et al. [8]IMRTYes31 mths (20–64 mths)66%—66%12% 
2DRTYes 46 mths (3–93 mths)72% 65%67% 
Garden et al. [25]IMRTYes (8%)45 mths (15–63 mths)————23.9 Gy
Daly et al. [26]†IMRTYes (87%)29 mths (4–105 mths)93%———33.2 Gy
Chao et al. [27]†IMRTYes (23%)33 mths (9–60 mths)86%——12%18.6 Gy
Huang et al. [28]IMRTYes33 mths (3–72 mths)92%——34%25.5 Gy
Setton et al. [29]†IMRTYes (88%)36.8 mths (3–135 mths)68%—28%29%25.8 Gy
Kwong et al. [34]IMRTNo24 mths (11–42 mths)82%——40% (1yrs) 15% (2yrs) 38.8 Gy
Wolden et al. [35]IMRTYes (93%)35 mths (3–74 mths)   32% (1yrs)35.2 Gy
Kam et al. [36]IMRTYes (30%)29 mths (8–45 mths)92% 75%23% (2yrs) 39 Gy
      16.7% (2yrs) 31 Gy
Lee et al. [38]IMRTYes (65%)31 mths (6–55 mths)—22%—33% 
Lee et al. [40]IMRTYes (75%)31 mths (7–72 mths)94%— 58% 
Liu et al. [41]IMRTYes (58%)13.0 mths (8–18 mths)—79%—53%37.8 Gy
Luo et al. [42] 3D-CRTNo58 mths (25–92 mths)74%12% 12%52.8 Gy
Al-Mamgani
et al. [47]		IMRT + 3D-CRTYes(28.3%)32 mths (7–172 mths)   14.1% 23.6 Gy
Lee et al. [50]IMRTYes (65%)26 mths (17–58 mths)48%  3.2%26 Gy
Van Gestel et al. [51]†IMRTYes
Def: 63%
Post: 23%		18.7 mths (0.13–51.7 mths)100%  44% 
Peponi et al. [52]†IMRTYes (85%)55 mths    Obj: 7.3 % Sub: 3.6%  
Gupta et al. [23]3D-CRT Yes40 mths (26–50 mths)93%   53 Gy
IMRT Yes (90%)40 mths (26–50 mths)77%   34.3 Gy
Lambrecht et al. [18]3D-CRTYes (80%)68 mths (37.2–104 mths)44%  68%53 Gy
IMRTYes (81%)35 mths (4.7–63.5 mths)32%  23%34 Gy
Toledano et al. [53]†IMRTYes (37.5%)25.3 mths (0.4–72 mths)~73%——~58% 
Clavel et al. [9]IMRTYes42 mths 75%  8% (2yrs) 
2-3DRTYes42 mths 77%  74% (2yrs) 
Vergeer et al. [20]†IMRTYes (43%)—   32% (6 mths)27 Gy
3D-CRTYes (35%)—   56% (6 mths)43 Gy
Chen et al. [21]*IMRTYes (9%)44 mths87%  36% 
3D-CRTYes (2%)44 mths89%  82% 
Nutting et al. [12]†IMRTYes (43%)44 mths93% 71%69%36.5 Gy
3D-CRTYes (40%)44 mths94% 91%76%61 Gy
Wong et al. [33]IMRTYes (70%)34 mths (9–50 mths)67.4%  2.3%30 Gy
Sultanem et al. [44]IMRTYes (91%)21.8 mths (5–49 mths)97%  28% 
Su et al. [45]IMRTNo50.9 mths (12–104 mths)73% 36%15.4% (1yrs) 9.0% (2yrs)31 Gy
Wang et al. [43]IMRTYes (83%)47.1 mths (11–68 mths)33.3% 4.7%12.3% (2yrs)27.6 Gy
Rades et al. [22]*2DRT Yes (8%) ~90%  73% 
3D-CRTYes (23%) ~90%  63% 
IMRTYes (6%) ~90%  17% 
Tham et al. [39]IMRTYes36.5 mths29% (Gr3) 3% (Gr3)  
IMRTNo36.5 mths20% (Gr3)    
Kim et al. [46] 3D-CRTNo48 mths57%  19% 
De Arruda et al. [32]†IMRTYes (86%)18 mths (8.4–76 mths)92% 60%33%26.5 Gy
Postoperative RT; †definitive and postoperative RT; all the rest: definitive RT.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.